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Objective: There is an urgent and compelling need to reduce the morbidity and expense of maintaining hemodialysis
vascular access patency. This large, long-term, retrospective, multicenter study, which compared access patency of
autogenous arteriovenous fistulas (AVF) and synthetic bridge grafts (AVG) created with conventional sutures or
nonpenetrating clips, was undertaken to resolve conflicting results from previous smaller studies.
Design: Patency data for 1385 vascular access anastomoses (clipped or sutured) was obtained from 17 hospitals and
dialysis centers (Appendix). Five hundred eighteen AVF (242 clip, 276 suture) and 827 AVG (440 clip, 384 suture) were
analyzed. Statistical comparisons were made with Kaplan-Meier survival analysis, log-rank test, two-sample t test, and X2
test. The Cox proportional hazards model was used to confirm Kaplan-Meier analysis.
Results: Access patency (primary, secondary, overall, and intention to treat) was significantly improved in access
anastomoses constructed with clips. In the intention-to-treat group, primary patency at 24 months was 0.54 for clipped
AVF and 0.34 for sutured AVF, andwas 0.36 for clipped AVG and 0.17 for sutured AVG. At 24months, primary patency
rate for AVF successfully used for dialysis was 0.67 for clips and 0.48 for sutures, and for AVGwas 0.39 for clips and 0.19
for sutured constructs. Interventions necessary to maintain patency were significantly fewer in clipped anastomoses.
Conclusion: Replacing conventional suture with clips significantly reduces morbidity associated with maintaining
permanent hemodialysis vascular access. This beneficial effect may be due to the biologic superiority of interrupted,
nonpenetrating vascular anastomoses. (J Vasc Surg 2003;38:229-35.)
The population with end-stage renal disease (ESRD) is
increasing at a rate of 6% per annum, and more than a
billion dollars is expended annually to maintain vascular
access patency and manage access-related complications.1-5
Anastomotic neointimal hyperplasia (ANH) resulting in
stenosis and eventual access occlusion remains the leading
cause of access failure.6,7 Interventions targeted at reducing
ANH by changing anastomotic hemodynamics with vein
cuffs, patches, and anastomotic angle, all based on conven-
tional suturing, have failed to improve patency.3,4 Thus,
despite a need to improve access patency, reducemorbidity,
and relieve a growing financial burden, there have been no
significant technical improvements since inception of the
procedure.3,5
Nonpenetrating arcuate legged clips that enable an
everted, elastomeric, flanged “blood-tight” anastomosis
with streamlined blood flow and improved hemodynamics
have recently been introduced into clinical practice (VCS;
US Surgical Corp/Tyco Inc).8 Experimental studies and
preliminary clinical reports have demonstrated the superi-
ority of clips for end-to-side and end-to-end vascular anas-
tomosis, with reduced ANH, improved patency, and appre-
ciated cost savings.9-12 Although improved long-term
patency of both clipped autogenous arteriovenous fistulas
(AVF) and synthetic bridge-graft fistulas (AVG) have been
reported,13,14 other single-institution studies have not con-
firmed patency differences.15,16
To resolve this important question, a long-term multi-
center retrospective study was undertaken to determine
whether clips have a beneficial effect on fistula patency
compared with conventional sutures. This report describes
the superior outcome of clipped vascular anastomoses on
vascular access patency.
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Table I. Patient distribution
Location
AVG AVF
Suture (N  384) Clip (N  443) Suture (N  276) Clip (N  242)
St Louis, Mo 76 (4) 104 (1) 63 (6) 60 (2)
Miami, Fla 55 (1) 44 47 (5) 57
Stockton, Calif 28 (1) 35 2 1
Tucson, Ariz 40 19 2 1
Portland, Ore 29 21 5 (1) 0
Detroit, Mich 24 (1) 27 8 5
Riverside, Calif 23 (1) 14 (1) 32 17 (1)
Baltimore, Md 24 19 15 10
Florence, SC 16 74 32 (1) 13 (1)
Opelousas, La 18 37 3 4
Hartford, Conn 9 18 5 8 (1)
Boston, Mass 1 0 0 8
Easton, Pa 7 (1) 4 19 12 (1)
Natick, Mass 4 1 32 35 (1)
Pittsburgh, Pa 9 10 2 (1) 0
Dallas, Tex 9 10 (3) 1 (1) 0
New Bedford, Mass 11 6 8 11
Thirty six of 40 excluded procedures appear in parenthesis. The other four were procedures without details on technique (Riverside, Calif, 3; Dallas, Tex, 1).
AVG, Arteriovenous graft; AVF, arteriovenous fistula.
Table II. Demographic data and risk factors
Variable
AVF AVG
Clip (n  199) Suture (n  199) Clip (n  401) Suture (n  344)
n % n % n % n %
Demographic data
Age, mean  SD
Gender
55.9  16.2 57.5  14.8 60.8  14.9 58.9  16.2
Male 146 73.3 126 63.3 157 39.1 149 43.3
Female 53 26.7 73 36.7 244 60.9 195 56.7
Race
White 77 38.7 93 46.7 106 26.4 102 29.7
African American 96 48.2 86 43.2 261 65.1* 189 54.9
Other 79 39.7 18 9 30 7.5* 45 13.1
Uncertain 7 3.5 2 1.0 4 1.0 8 2.3
Renal disease
Intrinsic 19 9.5 26 13.1 24 6.0 27 7.8
Congenital 6 3.0 8 4.0 6 1.5 3 0.9
Systemic 138 69.3 131 65.8 317 79.1 271 78.8
Uncertain 36 18.1 34 17.1 54 13.5 43 12.5
Access location
Radiocephalic 114 57.3 96 48.2 174 43.4 148 43.0
Brachiocephalic or
basilic
51 25.6 69 34.6 81 20.2 68 19.8
Thigh 9 4.5 24 12.1 23 5.7 14 4.1
Uncertain 25 12.6 10 5.0 123 30.7 114 33.1
Risk Factors
Diabetes
Yes 81 40.7 77 38.7 216 53.9 165 48.0
No 113 56.8 113 56.8 168 41.9 153 44.5
Uncertain 5 2.5 9 4.5 17 4.2 26 7.6
Erythropoietin therapy
Yes 102 51.3 95 47.7 200 49.9 149 43.3
No 85 42.7 94 47.2 178 44.4 168 48.8
Uncertain 12 6 10 5.0 23 5.7 27 7.8
Albumin 3 g/L
Yes 18 9 17 8.5 16 4 20 5.8
No 153 76.9 157 78.9 335 83.5 274 79.7
Uncertain 28 14.1 25 12.6 50 12.5 50 14.5
AVF, Arteriovenous fistula; AVG, arteriovenous graft.
*P  .01; all others nonsignificant (within access type).
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METHODS
Patency, morbidity, and demographic data were ana-
lyzed for 1385 fistulas (541 AVF, 844 AVG) placed in 1110
patients at 17 institutions by 21 different surgeons between
January 1996 and June 1999 (Table I). Individual cases
were tracked with examination of hospital, office, and dial-
ysis center records to acquire duration of primary, assisted
primary, secondary, and overall patency.17 Fistulas with
both arterial and venous anastomoses, or the venous anas-
tomosis of the AVG, constructed with clips, comprised the
clip cohort. Renal disease and factors that affect fistula
survival, eg, diabetes, erythropoietin (EPO) therapy, and
serum albumin concentration, were also documented (Ta-
ble II).
Primary patency duration is defined as time from fistula
placement to first intervention or occlusion. Assisted pri-
mary patency duration is time from fistula placement to first
occlusion in fistulas with previous surgical or endovascular
interventions. Secondary patency duration is defined as
time from fistula placement to fistula abandonment because
of nonfunction or occlusion, for fistulas with previous
successful interventions to treat thrombosis. Overall pa-
tency duration is defined as total number of fistulas in use
for dialysis at the end of the study. Patency comparisons
were performed only for fistulas used successfully for dial-
ysis (five consecutive treatments). Excluded from patency
comparisons were fistulas with uncertain placement date or
anastomotic technique, fistulas with incomplete follow-up
data, fistulas that failed to mature, fistulas that were patent
but not used, and fistulas that occluded before use. To
eliminate exclusion bias, intention-to-treat analysis was also
performed for all fistulas with complete data (Table III).
Intention to treat was defined as all AVF or AVG proce-
dures intended to be used for successful dialysis, in essence,
all graft or fistula procedures. All cases with complete
follow-up data were included in intention-to-treat patency
analysis. The biostatistical group at a nonparticipating cen-
ter (Center for Health Research, Loma Linda University
School of Public Health) performed data collation and
analysis. Data entered were verified at each participating
center by the respective investigator. A different reviewer at
the four centers that performed most procedures again
verified accuracy of data collection.
Statistical methods. Patency of AVF and AVG
(clipped versus sutured) were compared with Kaplan-Meier
survival analysis and log-rank test. Demographic data and
risk factors were compared with an independent two-sam-
ple t test for continuous variables and X2 test for nominal
variables. Differences resulting in P  .05 were considered
significant. A Cox proportional hazards model was used to
confirm the results of Kaplan-Meier analysis for primary
patency alone, because there were too few cases for the
multivariate Cox model to be appropriate for other patency
data.
RESULTS
Comparative patency: AVF. Three hundred ninety-
eight AVF (199 clip, 199 suture) in 382 patients (derived
from 541 access procedures in 488 patients) qualified for
patency analysis over the 40-month study period. One
hundred forty-three AVF (50 clip, 92 suture, 1 uncertain
anastomotic technique) were excluded: 77 became (14%)
occluded before maturation, 43 (8%) remained patent but
were not used for dialysis, and 23 (4%) lacked complete
follow-up data (Table III). Demographic data, cause of
renal disease, and risk factors for thrombosis were similar
Table III. Exclusions
AVF (n  541)* AVG (n  844)*
Clip Suture Clip Suture
n % n % n % n %
Recruited 249 291 445 396
Exclusions
Occluded 31 12.4 46 15.8 39 8.8 43 10.8
Failed to mature or not used 12 4.8 31 10.7† 0 0
Follow-up data incomplete‡ 5 2.0 11 3.8 5 1.1 9 2.3
Date of placement unknown‡ 2 0.08 4 1.4 0 0
Remaining for Analysis 199 79.9 199 68.4 401 90.1 344 86.9
AVF, Arteriovenous fistula; AVG, arteriovenous graft.
*Attachment method unknown for 1 AVF and 3 AVG.
†P  .05.
‡Excluded from intention-to-treat analyses.
Table IV. Postoperative complications
AVF AVG
Clip
(n  199)
Suture
(n  199)
Clip
(n  401)
Suture
(n  244)
Steal 5 4 11 9
Infection 4 7 13 26*
Bleeding 0 9† 6 7
Nerve injury 0 0 1 1
AVF, Arteriovenous fistula; AVG, arteriovenous graft.
*P  .05.
†P  .01.
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for both groups (Table II). Postoperative bleeding oc-
curred more frequently with sutures (P  .01) (Table IV).
Primary patency was significantly improved in the clip
group (P  .007; Fig 1, A). Assisted primary patency
between the groups did not reach statistical significance (P
 .26), but the number of fistulas that required interven-
tions was small (Table V). Secondary patency (P .07) was
marginally better in the suture anastomosis group (Fig 2,
A). Overall patency of the clip AVF cohort was significantly
improved (P  .02; Table V).
To maintain patency during the study period, 82 sec-
ondary procedures were performed in 53 AVF (28 clip, 54
suture). The number of secondary procedures per fistula
ranged between one (n  38) and five (n  1). Clipped
AVF required 0.22 procedures per fistula-year to maintain
patency, compared with 0.37 procedures per fistula-year for
sutured AVF (P  .001) (Table VI).
Of 541 AVF, 518 (276 suture, 242 clip) qualified for
intention-to-treat analysis. Twenty-three AVF (7 clip, 15
suture, 1 uncertain) with incomplete data were excluded
(Table III). A significantly improved primary patency rate
(P .0003; Fig 3, A) and overall patency rate (P .0002;
Table V was found for clip AVF. No difference was ob-
served in secondary intention-to-treat patency, because of
small numbers (Fig 4, A).
AVF were performed by 22 different surgeons; 6 sur-
geons performed 15 or more procedures. Sets of indicator
variables were created to test for surgeon effect and location
effect. A Cox model was created, with sex, age, surgeon,
clip or suture, and location included as independent vari-
ables. This model was used to analyze primary patency data.
After controlling for the above-mentioned covariates, clips
continued to be significantly protective over sutures (odds
ratio, 0.58; P  .008).
Comparative patency: AVG. Seven hundred forty-
five AVG (401 clip, 344 suture) of 844 procedures qualified
for patency comparisons. Ninety-nine AVG (44 clip, 52
suture, 3 uncertain) were excluded: 82 AVG (39 clip, 43
suture) became occluded or were abandoned within 2
months after placement, and follow-up data were incom-
plete for 14 (Table III). Demographic data, cause of renal
disease, and risk factors were similar for patients in both
groups, except for a difference in racial distribution (Table
II). There were more African American and nonwhite
patients in the clip group. Seventy-four complications were
encountered, with significantly lower infections in the
clipped cohort (Table IV).
Primary, secondary (Figs 1, B, and 3, B), and overall
patency rates were significantly improved in the clip AVG
group (P  .0001, P  .007, and P  .001, respectively;
Table V). To maintain patency, 635 secondary procedures
were performed in 293 AVG during the study. Procedures
per fistula ranged between one (n  149) and 15 (n  1).
Table VI. Revisions
AVF AVG
Clip
(n  199)
Suture
(n  199)
Clip
(n  401)
Suture
(n  344)
Fistula-years 127 146 312 212
Revisions 28 54 268 367
Revisions per
fistula-year
0.22* 0.37 0.86† 1.73
AVF, Arteriovenous fistula; AVG, arteriovenous graft.
*P  .05.
†P  .001.
Table V. Patency survival: Clip vs suture for AVF and AVG access
Patency
Clip Suture
P*n
Mean survival
(mo) n
Mean survival
(mo)
AVF
Primary 199 28 199 24 .0072
Primary ITT 242 23 276 18 .0003
Primary assisted 11 34 22 22 .26
Primary assisted ITT 15 25 24 20 NS
Secondary 12 24 13 29 .0673
Secondary ITT 14 24 20 20 NS
Overall 199 34 199 29 .024
Overall ITT 242 29 276 21 .0002
AVG
Primary 401 20 344 14 .0001
Primary ITT 443 19 384 13 .0001
Primary assisted 70 22 50 20 NS
Primary assisted ITT 72 22 58 17 .067
Secondary 95 27 119 20 .0067
Secondary ITT 106 24 128 19 .0304
Overall 401 31 344 24 .0001
Overall ITT 443 29 384 22 .0001
AVF, Arteriovenous fistula; AVG, arteriovenous graft; ITT, intention to treat; NS, not significant.
*Log-rank test.
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Sixty-eight AVG required two revisions, 38 required three
revisions and 15 required four revisions. Clipped AVG
required 0.86 procedures per fistula-year, compared with
1.73 for sutured constructs, to maintain patency (P  .05;
Table VI).
Intention-to-treat analysis was performed for 827 (443
clip, 384 suture) of 844 AVG; 17 were excluded because of
incomplete technical or follow-up data (Table III). Primary
(P  .0001; Fig 3, B), secondary (P  .03; Fig 4, B), and
overall patency (P  .0001; Table V) rates were signifi-
cantly improved in the clip group.
Six of 21 surgeons involved in AVG construction per-
formed more than 20 procedures each. Sets of indicator
variables were created to test surgeon and location effect. A
Cox model was created, with sex, age, surgeon, clip or
suture, and location included as independent variables.
This model, when applied to primary patency rate, showed
a significant benefit for clips over sutures (odds ratio, 0.67;
P  .001).
DISCUSSION
This 40-month, multicenter retrospective study shows
significantly improved patency and reduced revision rates
for clipped AVF and AVG compared with conventionally
sutured constructs. These data emphasize the importance
of the vascular anastomotic technique on vascular access
patency. This single modification of a standard surgical
procedure enables a significant reduction in morbidity, and
could result in decreased financial burden on third-party
payors such as Medicare. This benefit is apparent when
overall patency rates of clipped and sutured AVG (P  
.0001) are compared. Other studies have reported 30% to
50% secondary patency rate for AVG at 2 years despite
extensive salvage procedures, a patency rate that is consis-
tent with our suture group.4 In this study, clipped AVGhad
a secondary patency rate of nearly 60% at 2 years.
The uniformly improved access patency rate observed
with an interrupted anastomosis performed with nonpen-
etrating clips confirms the positive trend reported earlier
Fig 1. Kaplan-Meier analysis of primary patency for AVF (A) and
AVG (B), with numbers remaining at risk.
Fig 2. Kaplan-Meier analysis of secondary patency for AVF (A)
and AVG (B), with numbers remaining at risk.
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from smaller, single-institution studies.14,15 A significant
difference in patency outcome between clipped and sutured
access was not apparent in other single-center studies with
smaller numbers of cases and shorter follow-up.15,16 Data
from one of the these centers are included in this analysis.15
Fistula failure, though most frequently due to ANH, is
multifactorial. Repeated needle sticks, tissue infiltration,
hemorrhage and hematoma, dialysis-related hypotension,
cytokine release, and local compression at needle stick sites
contribute to loss of patency.5 ANH, the common cause for
access failure, is difficult to evaluate with direct tissue
examination, because this requires biopsy of the anasto-
motic region. Indirect evidence for ANH is loss of access
patency. It is postulated that the unique nonpenetrating
quality of the vascular clip enables rapid healing, reduces
compliance mismatch, and provides a “blood-tight” inter-
rupted anastomosis.9,18,19 Unlike sutured anastomoses, no
intraluminal material is present at the clipped anastomotic
line, minimizing endothelial and vessel wall trauma and
inflammatory tissue response. These biologic and hemody-
namic differences between clip and suture anastomoses,
particularly the end-to-side construct, may account for the
beneficial effects of clips.
Data acquisition and analysis for hemodialysis access
outcomes is problematic with regard to accuracy and reli-
ability, because the surgeon is only part of the multidisci-
plinary team that cares for patients with ESRD. Follow-up,
particularly in large institutions, is often fragmented, and
until recently there were no universally accepted definitions
and reporting standards for data analysis.17 To ensure
accuracy and reliability of our analysis, a number of safe-
guards were instituted during data collection and entry.
The number of procedures excluded because of inaccurate
information and incomplete follow-up was small (AVF,
5.8%; AVG, 2.7%). Exclusions because of early occlusion
were 14% for AVF and 9% for AVG, an incidence consistent
with previously reported studies.20,21 Fistulas (AVF, 8%;
AVG, 0%) patent at data analysis but not yet used for
dialysis were also excluded. The positive results in the
Fig 3. Kaplan-Meier analysis of primary patency for AVF (A) and
AVG (B) intention-to-treat cohorts, with numbers remaining at
risk.
Fig 4. Kaplan-Meier analysis of secondary patency for AVF (A)
and AVG (B) intention-to-treat cohorts, with numbers remaining
at risk.
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intention-to-treat analysis of the entire cohort of AVF and
AVG provide further validation of these results.
This large retrospective study of consecutive access
procedures over a 40-month period is a reasonable alterna-
tive to the ideal double-blind prospective, randomized trial.
In agreement with our results, previous smaller randomized
prospective studies have also demonstrated superior pa-
tency for clipped vascular access.11,13
Three factors can influence the validity of our results:
center effects, surgeon effects, and time effects. Although
two academic centers (University of Miami Medical Center
and Washington University School of Medicine) contrib-
uted most cases (35%), the distribution of access proce-
dures over the course of the study shows an equivalent
number of evaluable sutured and clipped anastomoses.
Thus no clustering of clipped or sutured procedures oc-
curred at any of the 17 centers. Although dialysis methods
vary among centers, the distribution of cases among aca-
demic and private dialysis units was similar. Data for this
study were extracted from centers distributed throughout
the United States, correcting for recognized regional diver-
sity of access management.22
Results can be biased by a surgeon effect, in which
degree of familiarity with technique has a role. In this study,
all surgeons were more experienced with sutures than with
clips; thus bias is weighted against clipped procedures.
Clips were generally introduced later in the individual series
as experience with the device was accrued; thus a clip
learning phase was inevitable. The same surgeons per-
formed both sutured and clipped procedures. During the
study period (January 1996 to June 1999) there were no
significant changes in dialysis techniques or vascular access
techniques (other than the clip itself) that would be likely to
substantially improve vascular access patency, thus obviat-
ing a time effect.
In conclusion, this multicenter study provides convincing
evidence that use of vascular clips rather than conventional
suture improves patency rate of vascular access for hemodial-
ysis. Clip usage results in significant cost savings in manage-
ment of ESRD, with reduction in surgical morbidity. These
results suggest that use of the clip in other cardiovascular
surgeries may have similar long-term beneficial effects.
We thank Ruby Chen of the Center for Health Re-
search, School of Public Health, Loma Linda University,
for data compilation and evaluation; and Linda Krueger of
Washington University School of Medicine and Jackie
Knecht of the Neurosurgery Center for Research, Training
and Education at Loma Linda University, for typing manu-
script revisions. We also thank Dr Richard Hirth of the
University of Michigan, Department of Health Manage-
ment and Policy, and the Kidney Epidemiology and Cost
Center, for review of the manuscript.
REFERENCES
1. System USRD. URDS 2001 Annual Report: atlas of end-stage renal
disease in the United States. Bethesda, Md: National Institute of
Diabetes and Digestive and Kidney Diseases; 2001.
2. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access
morbidity. J Am Soc Nephrol 1996;7:523-35.
3. Brescia MJ, Cimino JE, Appel K, Hurwich BJ. Chronic hemodialysis
using venipuncture and a surgically created arteriovenous fistula. N Engl
J Med 1966;275:1089-92.
4. Hakim R, Himmelfarb J. Hemodialysis access failure: a call to action.
Kidney Int 1998;54:1029-40.
5. Henderson LW. Future developments in the treatment of end-stage
renal disease: a North American perspective. Am J Kidney Dis 2000;
35(1 suppl):S106-16.
6. Roy-Chaudhury P, Kelly BS, Miller MA, et al. Venous neointimal
hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 2001;
59:2325-34.
7. Sukhatme VP. Venous access stenosis: prospects for prevention and
therapy. Kidney Int 1996;49:1161-74.
8. Kirsch WM, Zhu YH, Wahlstrom E, Wang ZG, Hardesty R, Oberg K.
Vascular reconstructions with nonpenetrating arcuate-legged clips. In:
Yao JST, Pearce WH, editors. Techniques in vascular and endovascular
surgery. New York, NY: Appleton & Lange; 1998. p 67-89.
9. Dal Ponte DB, Berman SS, Patula VB, Kleinert LB, Williams SK.
Anastomotic tissue response associated with expanded polytetrafluoro-
ethylene access grafts constructed by using non-penetrating clips. J Vasc
Surg 1999;30:325-33.
10. Stansby G, Knez P, Berwanger CS, Nelson K, Reichert V, Schmitz-
Rixen T. Does vascular stapling improve compliance of vascular anas-
tomoses? Vasc Surg 2001;35:115-21.
11. Schild AF, Raines J. Preliminary prospective randomized experience
with vascular clips in the creation of arteriovenous fistulae for hemodi-
alysis. Am J Surg 1999;178:33-7.
12. Cope C, Lee K, Stern H, Pennington D. Use of the vascular closure
staple clip applier for microvascular anastomosis in free-flap surgery.
Plast Reconstruc Surg 2000;24:377-82.
13. Schild AF, Pruett CS, Martin I, et al. The utility of the VCS clip for
creation of vascular access for hemodialysis: long-term results and
intraoperative benefits. Cardiovasc Surg 2001;9:526-30.
14. Haruguchi H, Nakagawa Y, Uchida Y, Sageshima J, Fuchinoue S,
Agishi T. Clinical application of vascular closure staple clips for blood
access surgery. ASAIO J 1998;44:M562-4.
15. Cook JW, Schuman ES, Standage BA, Heinl P. Patency and flow
characteristics using stapled vascular anastomoses in dialysis grafts. Am J
Surg 2001;181:24-7.
16. Cooper BZ, Flores L, Ramirez JA, et al. Analysis of nonpenetrating clips
versus sutures for arterial venous graft anastomosis. Ann Vasc Surg
2001;15:7-12.
17. Sidaway AN, Besarab A, Henry M, Ascher E, et al. Recommended
standards for reports dealing with arteriovenous hemodialysis accesses. J
Vasc Surg 2002;35:603-10.
18. Baguneid MS, Goldner S, Fulford PE, Hamilton G, Walker MG,
Seifalian AM. A comparison of para-anastomotic compliance profiles
after vascular anastomosis: non-penetrating clips versus standard su-
tures. J Vasc Surg 2001;33:812-20.
19. Leppa¨niemi AK, Wherry DC, Soltero RG, Pikoulis E, Hufnagel HV,
Fishback N, et al. A quick and simple method to close vascular, biliary,
and urinary tract incisions using the new vascular closure staples: a
preliminary report. Surg Endosc 1996;10:771-4.
20. Miller PE, Carlton D, Deierhoi MH, Redden DT, Allon M. Natural
history of arteriovenous grafts in hemodialysis patients. Am JKidneyDis
2000;36:68-74.
21. Miller PE, Tolwani A, Luscy CP, et al. Predictors of adequacy of
arteriovenous fistulae in hemodialysis patients. Kidney Int 1999;56:
275-80.
22. Hirth RA, Turenne MN, Woods JD, et al. Predictors of type of vascular
access in hemodialysis patients. JAMA 1996;276:1303-08.
Submitted Mar 5, 2002; accepted Feb 18, 2003.
Additional material for this article may be found online
at www.mosby.com/jvs.
JOURNAL OF VASCULAR SURGERY
Volume 38, Number 2 Shenoy et al 235
APPENDIX, online only
Participants in the multicenter vascular access study
who contributed cases for analysis are as follows: Alan S.
Coulson, MD, PhD, Dameron Heart Institute, Stockton,
Calif; Normand Miller, MD, Luis A. Queral, MD, The
Vascular Center, MercyMedical Center andUnionMemo-
rial Hospital, Baltimore, Md; Bobby Nibhanupudy, MD,
University of Texas Southwestern Medical Center, Dallas,
Tex; Stanley Byshe, MD, Susan Forlifer, Kevin Stitely,
Easton Memorial Hospital, Easton, Md; David Schaffer,
MD, Boston, Mass; Scott Berman, MD, Tucson, Ariz;
Francisco Escobar, MD, Henry Ford Hospital, Detroit,
Mich; SatishMuluk, MD, University of PittsburghMedical
Center, Pittsburgh, Pa; Blayne Standage, MD, Portland,
Ore; Surendra Shenoy, MD, Barnes Hospital, Washington
University, St Louis, Mo; Arnold Miller, MD, Metrowest
Surgical Associates, HarvardMedical School, Natick, Mass;
A. Frederick Schild, MD, Jackson Memorial Hospital, Mi-
ami, Fla; James D. Simpson, MD, Kaiser Permanente,
Riverside, Calif; Leslie Stewart, MD, McLeod Regional
Medical Center, Florence, SC; Elliott Badder, MD, Mercy
Medical Center, Baltimore, Md; Roger Rosen, MD, New
Bedford, Mass; Lewis Brown, MD, Hartford, Conn; Kerry
T. Thibodeaux, MD, Opelousas General Hospital, Ope-
lousas, La.
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